Indonesia

Tuberculosis profile

| High TB burden | High HIV burden | High MDR-TB burden |

Population 2013
Estimates of TB burden * 2013
Mortality (excludes HIV+TB)
Mortality (HIV+TB only)
Prevalence (includes HIV+TB)
Incidence (includes HIV+TB)
Incidence (HIV+TB only)
Case detection, all forms (%)
Estimates of MDR-TB burden * 2013
% of TB cases with MDR-TB
MDR-TB cases among notified pulmonary
TB cases

250 million
Number (thousands)
64 (3693)
3.9 (2.26.2)
680 (3401 100)
460 (410520)
15 (8.720)
71 (6380)
New
1.9 (1.42.5)
5 700 (4 2007 500)

Rate
(per 100 000 population)
25 (1437)
1.6 (0.872.5)
272 (138450)
183 (164207)
5.8 (3.57.8)

***
(Rate per 100 000 population per year)
80
40
0
1990

1994

1998

2002

2006

2010

2006

2010

Mortality (excludes HIV+TB)

Retreatment
12 (8.117)

(Rate per 100 000 population)

800

1 100 (7701 600)

400
TB case notifications 2013
Pulmonary, bacteriologically confirmed
Pulmonary, clinically diagnosed
Extrapulmonary

New **
196 310
103 888
17 420

Total new and relapse

Previously treated, excluding relapses
Total cases notified

325 582
1 521
327 103

Relapse
6 406
1 558

New
53 (<1%)

TB/HIV 2013
TB patients with known HIV status
HIV-positive TB patients
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)
HIV-positive TB patients on antiretroviral therapy (ART)
HIV-positive people screened for TB
HIV-positive people provided with IPT
Treatment success rate
New and relapse cases registered in 2012
Previously treated cases, excluding relapse, registered in 2012
HIV-positive TB cases, all types, registered in 2012
RR-/MDR-TB cases started on second-line treatment in 2011
XDR-TB cases started on second-line treatment in 2011
Laboratories 2013
Smear (per 100 000 population)
Culture (per 5 million population)
Drug susceptibility testing (per 5 million population)
Sites performing Xpert MTB/RIF
Is second-line drug susceptibility testing available?
Financing TB control 2014
National TB programme budget (US$ millions)
% Funded domestically
% Funded internationally
% Unfunded
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history

1994

1998

2002

Prevalence
(Rate per 100 000 population per year)
200

Among 325 582 new and relapse cases:

26 054 (8%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013
Cases tested for RR-/MDR-TB
Laboratory-confirmed RR-/MDR-TB cases
Patients started on MDR-TB treatment

0
1990

100

Retreatment
3 740 (39%)

Number
7 631
1 599
477
332
22 190

Total **
3 838
912
809
(%)
(2)
(21)
(30)
(21)

0
1990

1994

2.2
0.4
0.2
23
Yes, in country

127
13%
30%
57%

2002

2006

Notified (new and relapse)

Incidence (HIV+TB only)

2010

Incidence

(Number of patients)
3000
2000
1000
0
2003

(%)
86
71
49
60
50

1998

2005

2007

2009

2011

HIV-positive TB patients
on CPT
on ART
Treatment success rate (%)
90
70
50
30
1995 1997 1999 2001 2003 2005 2007 2009 2011
New
Retreatment
New and relapse
Retreatment, excluding
relapse
HIV-positive
RR-/MDR-TB
XDR-TB
Total budget (US$ millions)
150
100
50
0
2010

__
__

2011

Funded domestically
Unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2015-02-23

2012

__

2013

2014

Funded internationally

Data: www.who.int/tb/data